Dusková Jarmila, Dohnálek Jan, Skálová Tereza, Petroková Hana, Vondrácková Eva, Hradílek Martin, Konvalinka Jan, Soucek Milan, Brynda Jirí, Fábry Milan, Sedlácek Juraj, Hasek Jindrich
Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovského nám. 2, 162 06 Praha 6, Czech Republic.
Acta Crystallogr D Biol Crystallogr. 2006 May;62(Pt 5):489-97. doi: 10.1107/S0907444906006718. Epub 2006 Apr 19.
Peptidomimetic inhibitors of human immunodeficiency virus-1 protease are successful lead substances for the development of virostatic drugs against HIV as the causative agent of acquired immunodeficiency syndrome (AIDS). The hydroxyethylamine isostere of the proteolytic cleavage intermediate provides a suitable replacement for the peptide bond. A series of acyclic pseudopeptide inhibitors with the hydroxyethylamine isostere varying in chiral carbon configuration and P'2 residue type were structurally analysed by single-crystal X-ray crystallography. The compounds inhibit HIV protease with subnanomolar inhibition constants and block viral replication in tissue cultures. Here, the structure of such a complex with the R configuration of the isosteric group (PDB code 1zsf) is presented together with newly available synchrotron data for a complex with the S stereoisomer of the inhibitor (PDB code 1zsr). Comparison of the structure and binding with other complexes of HIV-1 protease and similar inhibitors contributes to the understanding of how these molecules bind to the wild-type form of this enzyme. The hydroxy group of the R stereoisomer interacts with one of the catalytic aspartic acids by a short hydrogen bond with rather extreme geometry. The change of configuration of the chiral carbon bearing the hydroxyl from S to R does not influence the inhibition efficiency in this case.
人免疫缺陷病毒-1蛋白酶的拟肽抑制剂是开发抗艾滋病(获得性免疫缺陷综合征,AIDS)病原体HIV的抗病毒药物的成功先导物质。蛋白水解裂解中间体的羟乙胺电子等排体为肽键提供了合适的替代物。通过单晶X射线晶体学对一系列具有不同手性碳构型和P'2残基类型的羟乙胺电子等排体的无环假肽抑制剂进行了结构分析。这些化合物以亚纳摩尔级的抑制常数抑制HIV蛋白酶,并在组织培养中阻断病毒复制。在此,展示了与等排基团R构型的此类复合物的结构(PDB代码1zsf)以及抑制剂S立体异构体复合物新获得的同步加速器数据(PDB代码1zsr)。将该结构和结合情况与HIV-1蛋白酶和类似抑制剂的其他复合物进行比较,有助于理解这些分子如何与该酶的野生型形式结合。R立体异构体的羟基通过具有相当极端几何形状的短氢键与其中一个催化天冬氨酸相互作用。在这种情况下,带有羟基的手性碳构型从S变为R并不影响抑制效率。